Substance / Medication

Interferon alfa-2a

Overview

Active Ingredient
interferon alfa-2a
RxNorm CUI
5879

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Clinical Trials

190 trials linked to this intervention

190
Total Trials
21
Recruiting
76
With Results

Research Evidence

Published studies and systematic reviews

Sort:
A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
Carrión José Antonio, Gonzalez-Colominas Elena, García-Retortillo Montserrat et al. · J Hepatol · 2013
PMID: 23811030RCT
Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial.
Mecenate Fabrizio, Pellicelli Adriano M, Barbaro Giuseppe et al. · BMC Gastroenterol · 2010
PMID: 20170514RCTFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Interferon alfa-2a (substance)
SNOMED CT
386914007
UMLS CUI
C0021734
RxNorm CUI
5879

Clinical Data

This intervention maps to 26 entities in the Ltrl knowledge graph.

20
Conditions
3
Biomarkers
2
Specialists
0
Symptoms
190
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.